Page last updated: 2024-09-04

cyc 202 and Nasopharyngeal Neoplasms

cyc 202 has been researched along with Nasopharyngeal Neoplasms in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chiao, J; Cui, CY; Dong, D; Goh, BC; Green, S; Hsieh, WS; Lai, YF; Lee, SC; Loh, T; Mow, B; Peh, BK; Salto-Tellez, M; Soh, D; Soo, R; Soong, R; Wong, LS	1
Alajez, NM; Frame, S; Green, SR; Hui, AB; Ito, E; Liu, FF; O'Sullivan, B; Shi, W; Yue, S	1

Other Studies

2 other study(ies) available for cyc 202 and Nasopharyngeal Neoplasms

Article	Year
Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-15, Volume: 15, Issue:4 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Apoptosis; Cell Cycle; Cyclin D1; DNA, Viral; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Nasopharyngeal Neoplasms; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine	2009
Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jun-01, Volume: 15, Issue:11 Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase 2; Caspase 3; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Cyclin-Dependent Kinases; DNA Breaks, Double-Stranded; Dose-Response Relationship, Drug; Humans; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Nasopharyngeal Neoplasms; Proto-Oncogene Proteins c-bcl-2; Purines; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; Roscovitine; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays	2009

Article

Year

Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-15, Volume: 15, Issue:4

Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Apoptosis; Cell Cycle; Cyclin D1; DNA, Viral; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Nasopharyngeal Neoplasms; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine

2009

Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jun-01, Volume: 15, Issue:11

Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase 2; Caspase 3; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Cyclin-Dependent Kinases; DNA Breaks, Double-Stranded; Dose-Response Relationship, Drug; Humans; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Nasopharyngeal Neoplasms; Proto-Oncogene Proteins c-bcl-2; Purines; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; Roscovitine; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays

2009